BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15246090)

  • 1. Drug design and synthesis of epsilon opioid receptor agonist: 17-(cyclopropylmethyl)-4,5alpha-epoxy-3,6beta-dihydroxy-6,14-endoethenomorphinan-7alpha-(N-methyl-N-phenethyl)carboxamide (TAN-821) inducing antinociception mediated by putative epsilon opioid receptor.
    Fujii H; Narita M; Mizoguchi H; Murachi M; Tanaka T; Kawai K; Tseng LF; Nagase H
    Bioorg Med Chem; 2004 Aug; 12(15):4133-45. PubMed ID: 15246090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational drug design of selective epsilon opioid receptor agonist TAN-821 and antagonist TAN-1014.
    Fujii H; Nagase H
    Curr Med Chem; 2006; 13(10):1109-18. PubMed ID: 16719773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational drug design and synthesis of a selective opioid receptor antagonist on the basis of the accessory site concept.
    Fujii H; Narita M; Mizoguchi H; Hirokawa J; Kawai K; Tanaka T; Tseng LF; Nagase H
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4241-3. PubMed ID: 15261278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
    Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
    J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (2S,3R) beta-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective delta-opioid receptor antagonist in mouse brain.
    Hosohata K; Varga EV; Alfaro-Lopez J; Tang X; Vanderah TW; Porreca F; Hruby VJ; Roeske WR; Yamamura HI
    J Pharmacol Exp Ther; 2003 Feb; 304(2):683-8. PubMed ID: 12538822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
    Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
    Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
    Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripherally mediated antinociception of the mu-opioid receptor agonist 2-[(4,5alpha-epoxy-3-hydroxy-14beta-methoxy-17-methylmorphinan-6beta-yl)amino]acetic acid (HS-731) after subcutaneous and oral administration in rats with carrageenan-induced hindpaw inflammation.
    Bileviciute-Ljungar I; Spetea M; Guo Y; Schütz J; Windisch P; Schmidhammer H
    J Pharmacol Exp Ther; 2006 Apr; 317(1):220-7. PubMed ID: 16339394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The roles of different subtypes of opioid receptors in mediating the nucleus submedius opioid-evoked antiallodynia in a neuropathic pain model of rats.
    Wang JY; Zhao M; Yuan YK; Fan GX; Jia H; Tang JS
    Neuroscience; 2006; 138(4):1319-27. PubMed ID: 16472929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of G-proteins in the mouse pons/medulla by beta-endorphin is mediated by the stimulation of mu- and putative epsilon-receptors.
    Mizoguchi H; Narita M; Nagase H; Tseng LF
    Life Sci; 2000 Oct; 67(22):2733-43. PubMed ID: 11105989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.
    Greiner E; Spetea M; Krassnig R; Schüllner F; Aceto M; Harris LS; Traynor JR; Woods JH; Coop A; Schmidhammer H
    J Med Chem; 2003 Apr; 46(9):1758-63. PubMed ID: 12699394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential involvement of mu(1)-opioid receptors in endomorphin- and beta-endorphin-induced G-protein activation in the mouse pons/medulla.
    Mizoguchi H; Narita M; Wu H; Narita M; Suzuki T; Nagase H; Tseng LF
    Neuroscience; 2000; 100(4):835-9. PubMed ID: 11036217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
    Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
    J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of the ameliorating effect on short-term memory impairment and antinociceptive effect of KT-90 in mice.
    Hiramatsu M; Hoshino T; Kanematsu K
    Behav Brain Res; 2005 May; 160(2):374-81. PubMed ID: 15863234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse.
    Mizoguchi H; Wu HE; Narita M; Hall FS; Sora I; Uhl GR; Nagase H; Tseng LF
    Neuroscience; 2002; 115(3):715-21. PubMed ID: 12435410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
    Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
    Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of a novel 6,14-epoxymorphinan derivative and its pharmacology.
    Nemoto T; Fujii H; Narita M; Miyoshi K; Nakamura A; Suzuki T; Nagase H
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6398-401. PubMed ID: 18990576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.
    McLamore S; Ullrich T; Rothman RB; Xu H; Dersch C; Coop A; Davis P; Porreca F; Jacobson AE; Rice KC
    J Med Chem; 2001 Apr; 44(9):1471-4. PubMed ID: 11311071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.
    Thomas JB; Zheng X; Mascarella SW; Rothman RB; Dersch CM; Partilla JS; Flippen-Anderson JL; George CF; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 1998 Oct; 41(21):4143-9. PubMed ID: 9767649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.